English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

t a s b t Liver cancer is the fifth most common malignant tumor in men and the ninth in women. An estimated 782,500 new cases occurred in the world during 2012.1 Most primary liver cancers worldwide are hepatocellular carcinoma (HCC), which likely accounts for 70--90% of cases. Globally it is the second leading cause of cancer death in men and the sixth among women, with about 745,500 deaths in 2012.1 It is one of the most fatal cancers, with five-year survival rates less than 20% even in developed countries. HCC incidence is increasing in areas with historically low rates, including parts of Oceania, Western Europe, and Northern America. In the United States, age-adjusted incidence rates of liver cancer more than tripled between 1975 and 2011.2 This increase is thought to be attributable to chronic hepatitis C virus (HCV) infection, mainly due to injection drug abuse, which was common in the 1960s and 1970s, and also to increases in the prevalence of obesity and diabetes mellitus.3,4 In Portugal, Marinho et al. revealed a 2.9-fold increase in hospital admissions for HCC in the twelve years studied (1993--2005), reaching 834 hospital admissions in 2005 (8.6/105).5

Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib